Women's Health

Abbott is committed to helping women live fuller lives.

Our quality menu includes tests for the detection or monitoring of cancers, as well as tests for pregnancy/fertility, congenital diseases and advanced methods for the detection of pre- and post- natal conditions. These diagnostic tests help health care professionals identify, treat and monitor medical conditions in women all over the world.

Pregnancy and Fertility

In addition to a full range of tests designed to assess fertility and detect pregnancy, Abbott also offers tests that help doctors monitor the health of both the mother and fetus..

• BhCG
• Estradiol
• FSH
• LH
• Progesterone
• Prolactin
• Testosterone*
• Total BhCG
• Thyroid Function During Pregnancy

Congenital

Congenital means existing at birth, or inborn.

• Cystic Fibrosis+
• CMV IgG
• CMV IgM
• Rubella IgG
• Rubella IgM
• Toxo IgG
• Toxo IgM

Pre/Post Natal

In addition to traditional testing, Abbott’s advancements in molecular diagnostics have resulted in pre- and post-natal testing at the DNA level.

• Alpha-fetoprotein (AFP) – Aids in the detection of fetal open neural tube defects
• Fetal Lung Maturity (FLM)y
• Vysis AneuVysion – rapid DNA-based prenatal diagnosis for the most common chromosome abnormalities
• Vysis TotelVysion – DNA-based detection of abnormalities of subtelomeres, the very ends of chromosomes

Cardiac Health

Breast Cancer receives a lot of attention as a women’s health issue and for good reason, but Heart Attacks kill 267,000 women annually which is six times more than breast cancer. Another 31,837 women die each year from congestive heart failure, representing 62.7% of all heart failure deaths. Since 1984, more women than men have died each year from heart disease, and the gap between men and women’s survival continues to widen.

Cancer

Early detection of a cancerous condition is often the key to long-term survival. Abbott’s diagnostic assays are used to detect or monitor cancer, including those specifically related to women’s cancer concerns.

Breast Cancer

• Vysis PathVysion – DNA-based assessment of HER-2 gene amplification in breast cancer patients
• CA 15-3™** -- Aids in the management of Stage II and III breast cancer patients

Ovarian Cancer

• CA 125™** -- Aids in monitoring ovarian cancer

+ Analyte specific reagent
* Product not available in the U.S.
** CA 15-3™ and CA 125™ are trademarks of Fujirebio Diagnostics, Inc.

Back to top